Ryan S. Bleeks.
TARRYTOWN, N.Y.—Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutics, has appointed Ryan S. Bleeks as chief executive officer. "We are excited to have Ryan join Visiox at this critical time for the organization," said Michael Derby, Visiox's founding investor and executive chairman. "His proven leadership in building teams, company infrastructure and executing successful launch strategies in the ophthalmics space will be instrumental as we accelerate our path toward commercialization."

Most recently Bleeks was the vice president of sales, sales training and sales operations at RVL Pharmaceuticals, where he was responsible for building the infrastructure, sales force and launch execution of Upneeq, the first product to treat acquired blepharoptosis in adults with an innovative prescription cash pay strategy. Prior to that, he was the national sales director at Sun Pharma responsible for the successful launches of Cequa and Xelpros.
Bleeks brings more than two decades of commercial experience, built on deep relationships in ophthalmology and optometry, which he established while launching more than 12 products in the eyecare space.
Visiox plans to submit two new drug applications to the U.S. FDA later this year in the glaucoma and cataract surgery markets.